- Cryoport, Inc. and SK pharmteco have announced a strategic partnership to offer integrated logistics and manufacturing services for biotechnology and pharmaceutical companies.
- The collaboration focuses on supporting the supply chain for small molecules, biopharmaceuticals, and cell and gene therapies.
Cryoport, Inc. and SK pharmteco have entered a strategic collaboration to provide integrated logistics and manufacturing services to biotechnology and pharmaceutical companies. This partnership combines Cryoport’s expertise in supply chain solutions with SK pharmteco’s contract manufacturing capabilities, creating a streamlined approach to delivering cell and gene therapy products.
Cryoport will leverage its cell and gene therapy support services, including biomaterial collection, shipping systems, and bioservices, to enhance SK pharmteco’s contract manufacturing operations. The collaboration will cover small molecules, biopharmaceuticals, and cell and gene therapies. Jerrell Shelton, CEO of Cryoport, stated, “We are delighted to be selected by SK pharmteco in supporting its manufacture of APIs and intermediates, biopharmaceuticals, and cell and gene therapies. This relationship aligns with Cryoport’s strategic goal to further diversify and enhance our revenue streams.”
Dana Cipriano, Vice President of Analytical Services at SK pharmteco, highlighted the growing importance of the cell and gene therapy sector, noting the critical role of a secure supply chain. “Partnering with Cryoport reflects our commitment to providing high-quality services tailored to meet the needs of our customers and the patients they serve,” said Cipriano.
Overview of outsourcing trends 
